Details

Autor(en) / Beteiligte

• Ayalon, Gai
• Lee, Seung-Hye
• Adolfsson, Oskar
• Foo-Atkins, Corinne
• Atwal, Jasvinder K
• Blendstrup, Mira
• Booler, Helen
• Bravo, Joseph
• Brendza, Robert
• Brunstein, Flavia
• Chan, Ruby
• Chandra, Priya
• Couch, Jessica A
• Datwani, Akash
• Demeule, Barthélemy
• DiCara, Danielle
• Erickson, Rich
• Ernst, James A
• Foreman, Oded
• He, Dongping
• Hötzel, Isidro
• Keeley, Michael
• Kwok, Michael C M
• Lafrance-Vanasse, Julien
• Lin, Han
• Lu, Yanmei
• Luk, Wilman
• Manser, Paul
• Muhs, Andreas
• Ngu, Hai
• Pfeifer, Andrea
• Pihlgren, Maria
• Rao, Gautham K
• Scearce-Levie, Kimberly
• Schauer, Stephen P
• Smith, William B
• Solanoy, Hilda
• Teng, Edmond
• Wildsmith, Kristin R
• Bumbaca Yadav, Daniela
• Ying, Yong
• Fuji, Reina N
• Kerchner, Geoffrey A

Titel

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease

Ist Teil von

• Science translational medicine, 2021-05, Vol.13 (593)

Ort / Verlag

United States

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Tau has become an attractive alternative target for passive immunotherapy efforts for Alzheimer's disease (AD). The anatomical distribution and extent of tau pathology correlate with disease course and severity better than other disease markers to date. We describe here the generation, preclinical characterization, and phase 1 clinical characterization of semorinemab, a humanized anti-tau monoclonal antibody with an immunoglobulin G4 (igG4) isotype backbone. Semorinemab binds all six human tau isoforms and protects neurons against tau oligomer neurotoxicity in cocultures of neurons and microglia. In addition, when administered intraperitoneally once weekly for 13 weeks, murine versions of semorinemab reduced the accumulation of tau pathology in a transgenic mouse model of tauopathy, independent of antibody effector function status. Semorinemab also showed clear evidence of target engagement in vivo, with increases in systemic tau concentrations observed in tau transgenic mice, nonhuman primates, and humans. Higher concentrations of systemic tau were observed after dosing in AD participants compared to healthy control participants. No concerning safety signals were observed in the phase 1 clinical trial at single doses up to 16,800 mg and multiple doses totaling 33,600 mg in a month.